To further improve Uromonitor® test performance, we analyzed a subset of samples (Uromonitor® + KRAS follow-up cohort) for another oncogene activated in bladder cancer, KRAS hotspot alterations, and compared follow-up recurrence detection to routinely used surveillance methods. Here, KRAS is linked to urinary bladder carcinoma.